{
    "id": 32885,
    "fullName": "AGGF1 - PDGFRB",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "AGGF1-PDGFRB results from the fusion of AGGF1 and PDGFRB, which leads to increased phosphorylation of Stat5, Akt, and Erk1/2 and transforming activity in cultured cells, and induced cytokine-independent cell growth in mouse models (PMID: 29434033). AGGF1-PDGFRB has been associated with acute lymphoblastic leukemia (PMID: 29434033).",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 55109,
        "geneSymbol": "AGGF1",
        "terms": [
            "AGGF1",
            "GPATC7",
            "GPATCH7",
            "HSU84971",
            "HUS84971",
            "VG5Q"
        ]
    },
    "variant": "AGGF1 - PDGFRB",
    "createDate": "03/25/2020",
    "updateDate": "04/02/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5159,
                "geneSymbol": "PDGFRB",
                "terms": [
                    "PDGFRB",
                    "CD140B",
                    "IBGC4",
                    "IMF1",
                    "JTK12",
                    "KOGS",
                    "PDGFR",
                    "PDGFR-1",
                    "PDGFR1",
                    "PENTT"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 21151,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing AGGF1-PDGFRB were sensitive to treatment with CHZ868 in culture, demonstrating reduced cell viability (PMID: 29434033).",
            "molecularProfile": {
                "id": 35561,
                "profileName": "AGGF1 - PDGFRB"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21153,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient with acute lymphoblastic leukemia harboring AGGF1-PDGFRB was sensitive to Gleevec (imatinib) treatment, demonstrating a fast leukemia clearance and a decrease in blast percentage from 51% to 3% within 8 weeks (PMID: 29434033).",
            "molecularProfile": {
                "id": 35561,
                "profileName": "AGGF1 - PDGFRB"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80144,
                "name": "childhood acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21148,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing AGGF1-PDGFRB and PDGFRB C843G demonstrated resistance to treatment with Sprycel (dasatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing AGGF1-PDGFRB and PDGFRB C843G demonstrated resistance to treatment with Tasigna (nilotinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21152,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing AGGF1-PDGFRB and PDGFRB C843G were sensitive to treatment with CHZ868 in culture, demonstrating reduced cell viability (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21154,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient harboring AGGF1-PDGFRB who initially responded to treatment with Gleevec (imatinib) experienced relapse and subsequent testing revealed PDGFRB C843G (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80144,
                "name": "childhood acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21150,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing AGGF1-PDGFRB and PDGFRB C843G demonstrated resistance to treatment with Iclusig (ponatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21147,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing AGGF1-PDGFRB and PDGFRB C843G demonstrated resistance to treatment with Gleevec (imatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35561,
            "profileName": "AGGF1 - PDGFRB",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35564,
            "profileName": "AGGF1 - PDGFRB PDGFRB C843G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}